
Please try another search
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Name | Age | Since | Title |
---|---|---|---|
Chi-feng Chang | - | 2024 | Independent Director |
Chi-Chuan Chen | 66 | 2013 | Director |
Tay-Chang Wang | - | 2021 | Independent Director |
Chun-Yen Chang | - | 2022 | Independent Director |
Allen Y. Chao | 79 | 2013 | Founder & Honorary Chairman |
Jang-Yang Chang | - | 2022 | Independent Director |
Shang-Hsien Hsieh | - | 2024 | Independent Director |
Pao-Shi Sheng | - | 2025 | Chairman of the Board |
Lin-Cheng Chen | 54 | 2023 | Director |
Stephen Lam | - | 2024 | CEO & Director |
Yen-Shu Chang | - | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review